#1 Clinical Trials Search in Europe

Elranatamab

Elranatamab is an innovative bispecific antibody being studied in clinical trials for the treatment of multiple myeloma, a type of blood cancer affecting plasma cells. This article explores the ongoing research into elranatamab’s safety and efficacy across various stages of multiple myeloma, from newly diagnosed to relapsed/refractory cases.

Table of Contents

What is Elranatamab?

Elranatamab, also known by its brand name Elrexfio or research code PF-06863135, is a new type of medication being developed to treat multiple myeloma[1]. Multiple myeloma is a type of blood cancer that affects plasma cells, which are white blood cells responsible for producing antibodies to fight infections[2].

This medication belongs to a class of drugs called bispecific antibodies. These are specially designed proteins that can bind to two different targets at the same time, making them potentially more effective than traditional treatments[3].

How Elranatamab Works

Elranatamab works in a unique way by targeting two specific proteins in the body:

  • BCMA (B-cell maturation antigen): This protein is found on the surface of multiple myeloma cells.
  • CD3: This protein is found on T-cells, which are a type of immune cell that helps fight diseases.

By binding to both BCMA and CD3, Elranatamab acts as a bridge between the cancer cells and the immune system’s T-cells. This connection activates the T-cells and directs them to attack and destroy the multiple myeloma cells[4]. This process is called targeted T-cell-mediated cytotoxicity, which means the T-cells are specifically guided to kill the cancer cells.

Conditions Treated by Elranatamab

Elranatamab is primarily being studied for the treatment of multiple myeloma, particularly in cases where the disease has:

  • Relapsed: The cancer has returned after a period of improvement
  • Refractory: The cancer is not responding to current treatments

It is being investigated for use in patients who have tried other treatments without success, including those who have received at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 antibody[5]. These are different types of medications commonly used to treat multiple myeloma.

Clinical Trials and Research

Elranatamab is currently being studied in several clinical trials to evaluate its safety and effectiveness. Some key studies include:

  • MagnetisMM-3: A phase 2 study looking at Elranatamab as a single treatment for patients with relapsed or refractory multiple myeloma[6].
  • MagnetisMM-4: An “umbrella” study examining Elranatamab in combination with other cancer treatments[7].
  • MagnetisMM-6: A phase 3 study comparing Elranatamab combinations to standard treatments in newly diagnosed multiple myeloma patients who are not eligible for stem cell transplant[8].

These trials are helping researchers understand how well Elranatamab works, what the best dosing regimens are, and how it compares to existing treatments.

How Elranatamab is Administered

Elranatamab is typically given as a subcutaneous injection, which means it is injected under the skin[4]. The treatment schedule may vary depending on the specific clinical trial or treatment plan, but it often involves:

  • An initial “step-up” dosing approach, starting with lower doses and gradually increasing to the full dose
  • Regular injections, often weekly or at longer intervals
  • Treatment cycles that last about 28 days each

Patients may receive Elranatamab until their disease progresses, they experience unacceptable side effects, or they choose to stop treatment[1].

Potential Side Effects

As with any medication, Elranatamab can cause side effects. Some potential side effects being monitored in clinical trials include:

  • Cytokine Release Syndrome (CRS): A condition where the immune system becomes overly activated, causing symptoms like fever, low blood pressure, and difficulty breathing[6].
  • Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): A neurological side effect that can cause confusion, difficulty speaking, or seizures[6].
  • Changes in blood cell counts
  • Fatigue
  • Nausea or vomiting

It’s important to note that not all patients will experience these side effects, and researchers are working to understand and manage them effectively.

Future Prospects and Ongoing Research

Elranatamab shows promise in the treatment of multiple myeloma, particularly for patients who have not responded well to other therapies. Ongoing research is exploring:

  • Its effectiveness when used alone or in combination with other drugs
  • Its potential use in newly diagnosed patients
  • Long-term safety and efficacy
  • Quality of life improvements for patients

As research continues, Elranatamab may become an important new option for multiple myeloma patients, potentially offering hope to those who have limited treatment choices[9].

Aspect Details
Drug Name Elranatamab (also known as PF-06863135 or Elrexfio)
Drug Type Bispecific antibody targeting CD3 and BCMA
Administration Subcutaneous injection
Indications Studied Newly diagnosed, relapsed, and refractory multiple myeloma; high-risk smoldering multiple myeloma; AL amyloidosis
Key Outcomes Measured Objective response rate, progression-free survival, overall survival, minimal residual disease negativity, safety and tolerability
Comparators Lenalidomide in some trials; single-arm studies in others
Notable Side Effects Cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, infections
Quality of Life Assessments EORTC QLQ-C30, EORTC QLQ-MY20, EQ-5D
Innovative Aspects Self-administration studies, post-CAR-T cell therapy consolidation, MRD-adapted treatment approaches

FAQ

  • What is elranatamab? Elranatamab is a bispecific antibody that targets both CD3 on T-cells and BCMA (B-cell maturation antigen) on multiple myeloma cells. It works by activating the patient's own T-cells to attack and kill myeloma cells.
  • What types of multiple myeloma is elranatamab being studied for? Elranatamab is being investigated for various stages of multiple myeloma, including newly diagnosed patients after stem cell transplant, relapsed or refractory cases, and even high-risk smoldering multiple myeloma.
  • How is elranatamab administered? Elranatamab is typically given as a subcutaneous (under the skin) injection. The dosing schedule may vary depending on the specific trial, but often includes step-up doses followed by regular maintenance doses.
  • What are some potential side effects of elranatamab? Common side effects being monitored in clinical trials include cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infections. The severity and frequency of these side effects are being closely studied.
  • How does elranatamab compare to current multiple myeloma treatments? Several trials are comparing elranatamab to existing treatments like lenalidomide. Researchers are evaluating if elranatamab can provide better outcomes in terms of progression-free survival, overall response rates, and quality of life for patients with multiple myeloma.

Ongoing Clinical Trials on Elranatamab

  • Study of Elranatamab for Patients with Multiple Myeloma Resistant to Proteasome Inhibitors, Immunomodulatory Drugs, and Anti-CD38 Antibodies

    Not recruiting

    2 1 1
    Investigated drugs:
    Belgium France Germany Poland Spain

  • Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Finland France Germany +7

  • Study of Elranatamab, Dexamethasone, and Diphenhydramine Hydrochloride for Patients with High-Risk Smoldering Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland France Greece Italy The Netherlands Norway

  • Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Finland France Germany +8

  • Study of Elranatamab for Treating Relapsed or Refractory Multiple Myeloma in Patients Previously Treated with Three Drug Classes

    Not recruiting

    2 1 1
    Investigated drugs:
    Spain

Glossary

  • BCMA: B-cell maturation antigen, a protein found on the surface of multiple myeloma cells that is targeted by elranatamab.
  • Bispecific antibody: A type of engineered antibody that can bind to two different targets simultaneously, in this case, CD3 on T-cells and BCMA on myeloma cells.
  • Cytokine release syndrome (CRS): A potential side effect of immunotherapy where the immune system becomes overly activated, leading to symptoms like fever, low blood pressure, and difficulty breathing.
  • ICANS: Immune effector cell-associated neurotoxicity syndrome, a potential neurological side effect of some cancer immunotherapies.
  • IMWG criteria: International Myeloma Working Group criteria, a standardized set of guidelines used to assess response to treatment in multiple myeloma.
  • Minimal Residual Disease (MRD): A small number of cancer cells that remain in the body during or after treatment, often detectable only by highly sensitive tests.
  • Multiple Myeloma: A type of blood cancer that develops in plasma cells, a type of white blood cell found in bone marrow.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives without the cancer getting worse.
  • Relapsed Multiple Myeloma: Multiple myeloma that returns after a period of improvement with treatment.
  • Refractory Multiple Myeloma: Multiple myeloma that does not respond to or stops responding to treatment.
  • Smoldering Multiple Myeloma: An early form of myeloma that does not yet cause symptoms or organ damage but may progress to active multiple myeloma.
  • Subcutaneous injection: A method of administering medication by injecting it into the tissue layer between the skin and the muscle.

References

  1. https://clinicaltrials.gov/study/NCT06057402
  2. https://clinicaltrials.gov/study/NCT05228470
  3. https://clinicaltrials.gov/study/NCT05675449
  4. https://clinicaltrials.gov/study/NCT05014412
  5. https://clinicaltrials.gov/study/NCT05462639
  6. https://clinicaltrials.eu/trial/study-of-elranatamab-for-patients-with-multiple-myeloma-resistant-to-proteasome-inhibitors-immunomodulatory-drugs-and-anti-cd38-antibodies/
  7. https://clinicaltrials.gov/study/NCT05090566
  8. https://clinicaltrials.gov/study/NCT05623020
  9. https://clinicaltrials.eu/trial/study-comparing-elranatamab-and-lenalidomide-for-patients-with-newly-diagnosed-multiple-myeloma-after-stem-cell-transplantation/